What are the typical total PSA level, free PSA level, and free‑to‑total PSA ratio in benign prostatic hyperplasia (BPH)?

PSA Levels in Benign Prostatic Hyperplasia

In men with BPH, total PSA levels typically range from 4-10 ng/mL (the "gray zone"), with a free-to-total PSA ratio generally >18-25%, which helps distinguish BPH from prostate cancer where the ratio is typically <18%. 1

Total PSA in BPH

The evidence consistently demonstrates significant overlap between BPH and prostate cancer in PSA values, particularly in the 4-10 ng/mL range:

• 30-35% of men with PSA between 4-10 ng/mL will have prostate cancer rather than BPH alone 1, 2
• PSA >10 ng/mL confers >67% likelihood of prostate cancer, making isolated BPH less likely at these levels 2
• Research data shows mean total PSA in BPH patients ranges from 4.1-6.4 ng/mL in various studies 3, 4, 5

Critical caveat: Total PSA alone cannot reliably distinguish BPH from cancer due to the 65% false-positive rate in the 4-10 ng/mL range 1. This is because PSA is actually more highly expressed per gram in hyperplastic tissue than in cancer tissue, making it arguably a better marker of BPH degree than cancer presence 1.

Free PSA and Free-to-Total Ratio in BPH

The free-to-total PSA ratio provides better discrimination than total PSA alone:

• BPH patients typically have free-to-total ratios of 20-32% 3, 6, 7
• A ratio <10% is highly suspicious for cancer 2
• Using an 18% cutoff: approximately 75-80% of BPH cases fall above this threshold, while 80-86% of cancer cases fall below it 8, 5

Research demonstrates mean free PSA levels in BPH range from 0.75-1.7 ng/mL 3, 6, with the ratio remaining relatively stable across different prostate volumes in BPH patients 9.

Important Clinical Considerations

Prostate volume significantly influences PSA interpretation:

• Both total and free PSA correlate strongly with prostate volume (p=0.0001-0.003) 6
• Patients with prostates <50 cm³ have an 11-fold increased odds of having a free-to-total ratio <18% even with BPH 6
• The free-to-total ratio loses discriminatory value in prostates >60 mL, where specificity drops significantly 9

Inflammation confounds interpretation:

• Acute or moderate-to-severe chronic-active prostatitis increases the free-to-total ratio (mean 27%) compared to inactive prostatitis (19%) 6
• Chronic prostatitis mimics cancer by decreasing the free-to-total ratio, similar to malignancy 7
• This creates diagnostic confusion that cannot be resolved by PSA testing alone

For men on 5-alpha reductase inhibitors (finasteride/dutasteride):

• PSA decreases by approximately 50% after 1 year of treatment 10
• The measured PSA should be doubled to accurately interpret cancer risk 10
• The free-to-total ratio remains constant because both decrease proportionally 10

Practical Algorithm for PSA Interpretation in Suspected BPH

When PSA is elevated in a patient with LUTS:

1. PSA ≤4.0 ng/mL: Low cancer risk (though 15% may still have cancer) 2
2. PSA 4-10 ng/mL ("gray zone"):
   • Measure free-to-total ratio
   • If ratio >25%: likely BPH, consider workup for benign disease 2
   • If ratio 18-25%: intermediate risk, consider additional biomarkers (phi >35, 4Kscore, PCA3) 2
   • If ratio <18%: high cancer suspicion, proceed to biopsy 8, 5
3. PSA >10 ng/mL: >67% cancer likelihood, proceed to biopsy regardless of ratio 2

Always assess prostate volume (ideally via TRUS or review existing imaging), as volume >60 mL significantly reduces the utility of the free-to-total ratio for cancer discrimination 9.